TerminatedNCT03352453
A Study of Rapastinel for Rapid Treatment of Depression and Suicide prevention in Major Depressive Disorder
Researchers are comparing Rapastinel and placebo to find out how the approaches affect depression symptoms in adults with depression.
Medication studyAges 18–65United States
Understand this study
What is this study about?
Researchers are comparing Rapastinel and placebo to find out how the approaches affect depression symptoms in adults with depression.
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Birmingham and 16 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 15, 2017
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 138
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03352453
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients With Major Depressive Disorder
Recruitment & locations
TerminatedBirmingham · Garden Grove · Glendale
14 more locations
- Panorama City
- Hartford
- Hialeah
- Oakland Park
- Atlanta
- Hoffman Estates
- Lake Charles
- Gaithersburg
- Las Vegas
- New York
- Cincinnati
- Richardson
- Roanoke
- Salem
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are comparing Rapastinel and placebo to find out how the approaches affect depression symptoms in adults with depression.
Who is behind this study?
The study sponsor is Naurex, Inc, an affiliate of Allergan plc.
Does this study involve medication?
Yes. The study involves medication, including Rapastinel and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as terminated.
